DE2137045A1 - Arzneimittelzubereitung - Google Patents
ArzneimittelzubereitungInfo
- Publication number
- DE2137045A1 DE2137045A1 DE19712137045 DE2137045A DE2137045A1 DE 2137045 A1 DE2137045 A1 DE 2137045A1 DE 19712137045 DE19712137045 DE 19712137045 DE 2137045 A DE2137045 A DE 2137045A DE 2137045 A1 DE2137045 A1 DE 2137045A1
- Authority
- DE
- Germany
- Prior art keywords
- thiazolyl
- thiourea
- methyl
- compound
- diethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims description 9
- 239000003814 drug Substances 0.000 title claims description 5
- 229940079593 drug Drugs 0.000 title claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 11
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 8
- -1 2-thiazolyl Chemical group 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 230000004060 metabolic process Effects 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 230000000078 anti-malarial effect Effects 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 239000012876 carrier material Substances 0.000 claims description 2
- 201000004792 malaria Diseases 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- ZAWPTHKVMMXVTH-UHFFFAOYSA-N 1-methyl-3-(1,3-thiazol-2-yl)thiourea Chemical compound CNC(=S)NC1=NC=CS1 ZAWPTHKVMMXVTH-UHFFFAOYSA-N 0.000 claims 2
- VQTRGMDNNYNBNG-UHFFFAOYSA-N 1,1-diethyl-3-(1,3-thiazol-2-yl)thiourea Chemical compound CCN(CC)C(=S)NC1=NC=CS1 VQTRGMDNNYNBNG-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 150000007979 thiazole derivatives Chemical class 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000003430 antimalarial agent Substances 0.000 description 2
- 229940033495 antimalarials Drugs 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LOCOYCNSPKQNRY-UHFFFAOYSA-N 1,3-thiazol-2-ylthiourea Chemical compound NC(=S)NC1=NC=CS1 LOCOYCNSPKQNRY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241000224017 Plasmodium berghei Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1124070 | 1970-07-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2137045A1 true DE2137045A1 (de) | 1972-01-27 |
Family
ID=4371509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19712137045 Pending DE2137045A1 (de) | 1970-07-24 | 1971-07-23 | Arzneimittelzubereitung |
Country Status (8)
| Country | Link |
|---|---|
| AU (1) | AU3041671A (enrdf_load_stackoverflow) |
| BE (1) | BE770403A (enrdf_load_stackoverflow) |
| DE (1) | DE2137045A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2100948B1 (enrdf_load_stackoverflow) |
| GB (1) | GB1330545A (enrdf_load_stackoverflow) |
| IL (1) | IL37235A (enrdf_load_stackoverflow) |
| NL (1) | NL7108189A (enrdf_load_stackoverflow) |
| ZA (1) | ZA714076B (enrdf_load_stackoverflow) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0540143A3 (enrdf_load_stackoverflow) * | 1991-08-02 | 1995-01-04 | Medivir Ab | |
| US5593993A (en) * | 1991-08-02 | 1997-01-14 | Medivir Ab | Method for inhibition of HIV related viruses |
-
1971
- 1971-06-15 NL NL7108189A patent/NL7108189A/xx unknown
- 1971-06-22 ZA ZA714076A patent/ZA714076B/xx unknown
- 1971-06-24 AU AU30416/71A patent/AU3041671A/en not_active Expired
- 1971-07-05 IL IL37235A patent/IL37235A/en unknown
- 1971-07-22 FR FR7126840A patent/FR2100948B1/fr not_active Expired
- 1971-07-23 GB GB3475871A patent/GB1330545A/en not_active Expired
- 1971-07-23 DE DE19712137045 patent/DE2137045A1/de active Pending
- 1971-07-23 BE BE770403A patent/BE770403A/xx unknown
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0540143A3 (enrdf_load_stackoverflow) * | 1991-08-02 | 1995-01-04 | Medivir Ab | |
| US5593993A (en) * | 1991-08-02 | 1997-01-14 | Medivir Ab | Method for inhibition of HIV related viruses |
| US5658907A (en) * | 1991-08-02 | 1997-08-19 | Medivir A/B | Compounds and methods for inhibition of HIV and related viruses |
| US5714503A (en) * | 1991-08-02 | 1998-02-03 | Medivir Ab | Compounds and methods for inhibition of HIV and related viruses |
Also Published As
| Publication number | Publication date |
|---|---|
| IL37235A (en) | 1973-10-25 |
| FR2100948B1 (enrdf_load_stackoverflow) | 1974-09-06 |
| GB1330545A (en) | 1973-09-19 |
| IL37235A0 (en) | 1971-10-20 |
| NL7108189A (enrdf_load_stackoverflow) | 1972-01-26 |
| BE770403A (fr) | 1972-01-24 |
| AU3041671A (en) | 1973-01-04 |
| ZA714076B (en) | 1972-03-29 |
| FR2100948A1 (enrdf_load_stackoverflow) | 1972-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3688296T2 (de) | Arzneimittel zur behandlung von erbrechen. | |
| DE3514054C2 (enrdf_load_stackoverflow) | ||
| DE3874917T2 (de) | Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen. | |
| DE3586920T2 (de) | Benzopyranverbindungen zur verwendung auf das kardiovaskulaere system. | |
| DE2555411A1 (de) | Pharmazeutische zusammensetzung mit einem n-substituierten pyridon | |
| DE3786893T2 (de) | Piperidinderivat zur Schmerzbehandlung. | |
| DE2523998A1 (de) | Pharmazeutische zubereitung fuer die behandlung der schizophrenie | |
| DE2823174A1 (de) | Arzneimittel fuer die prophylaktische behandlung postoperativer tiefer venenthrombose | |
| DE69420776T2 (de) | Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer | |
| DE69005978T2 (de) | Verwendung von Actinonin zur Herstellung eines Medikamentes zur Inhibierung der Angiogenese. | |
| DE3779842T2 (de) | Antiallergisches mittel. | |
| DE3419935A1 (de) | Verwendung von hydroxyindolderivaten bei der senkung des blutdrucks | |
| DE69115528T2 (de) | Neue pharmazeutische Verwendungen von Forskolin-Derivaten | |
| DE2212840A1 (de) | Mittel zur Behandlung kardiovaskulaerer Stoerungen und pharmazeutische Praeparate zu seiner Anwendung | |
| DE2137045A1 (de) | Arzneimittelzubereitung | |
| DE69004529T2 (de) | Verwendung von Sertralin zur Behandlung von Abhängigkeiten von chemischen Stoffen. | |
| DE2528460A1 (de) | Verwendung von l-carboxamido-2- cyan-aziridin als immunstimulans | |
| DE69528068T2 (de) | Conagenine zur prävention und behandlung von diarrhöe | |
| DE60005526T2 (de) | Verwendung von 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine zur behandlung von erkrankungen des magen-darm-traktes | |
| DE69302250T2 (de) | Verwendung von Isoquinolinon-Derivaten zur Behandlung von Hyperlipoproteinemia | |
| DE4217396A1 (de) | Metrifonat enthaltendes Arzneimittel | |
| DE2501649C3 (de) | Thiophen-2-carbonsäuresalz des Papaverins, Verfahren zu seiner Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| EP0342565A2 (de) | Verwendung des Thiazol-Derivates Tiprotimod zur Herstellung eines Mittels zur Therapie von Virusinfektionen | |
| EP0281608A1 (de) | Hydroxyindolderivat. | |
| DE1963223A1 (de) | Mittel zur Behandlung von Virusinfektionen |